103 related articles for article (PubMed ID: 7962467)
41. Distinct temporal and spatial activities of RU486 on progesterone receptor function in reproductive organs of ovariectomized mice.
Han SJ; Tsai SY; Tsai MJ; O'Malley BW
Endocrinology; 2007 May; 148(5):2471-86. PubMed ID: 17303655
[TBL] [Abstract][Full Text] [Related]
42. [Antagonist and agonist effects of the antiprogesterone RU 486].
Schaison G
Ann Endocrinol (Paris); 1989; 50(3):200-7. PubMed ID: 2683974
[TBL] [Abstract][Full Text] [Related]
43. Investigations on sterols. 38. Synthesis of 1,2 -methylene-17 -acetoxy-9 ,10 -pregnanes, a class of potent progestational agents.
Halkes SJ; Hartog J; Morsink L; de Wachter AM
J Med Chem; 1972 Dec; 15(12):1288-92. PubMed ID: 4635976
[No Abstract] [Full Text] [Related]
44. The effect of the antiprogestins RU 486 and ZK 98734 on the synthesis and metabolism of prostaglandins F2 alpha and E2 in separated cells from early human decidua.
Smith SK; Kelly RW
J Clin Endocrinol Metab; 1987 Sep; 65(3):527-34. PubMed ID: 3476490
[TBL] [Abstract][Full Text] [Related]
45. New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties.
Giannoukos G; Szapary D; Smith CL; Meeker JE; Simons SS
Mol Endocrinol; 2001 Feb; 15(2):255-70. PubMed ID: 11158332
[TBL] [Abstract][Full Text] [Related]
46. Antioxidant: a new role for RU-486 and related compounds.
Parthasarathy S; Morales AJ; Murphy AA
J Clin Invest; 1994 Nov; 94(5):1990-5. PubMed ID: 7962545
[TBL] [Abstract][Full Text] [Related]
47. Glucocorticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion.
Peeters BW; Tonnaer JA; Groen MB; Broekkamp CL; van der Voort HA; Schoonen WG; Smets RJ; Vanderheyden PM; Gebhard R; Ruigt GS
Stress; 2004 Dec; 7(4):233-41. PubMed ID: 16019588
[TBL] [Abstract][Full Text] [Related]
48. Trophoblastic and decidual response to RU486: effects on human chorionic gonadotrophin, human placental lactogen, prolactin and pregnancy-associated plasma protein-A production in vitro.
Bischof P; Sizonenko MT; Herrmann WL
Hum Reprod; 1986 Jan; 1(1):3-6. PubMed ID: 2458379
[TBL] [Abstract][Full Text] [Related]
49. Determination of conformational changes in the progesterone receptor using ELISA-like assays.
Pullen MA; Laping N; Edwards R; Bray J
Steroids; 2006 Sep; 71(9):792-8. PubMed ID: 16784762
[TBL] [Abstract][Full Text] [Related]
50. The progesterone receptor. Biological effects of progestins and antiprogestins.
Savouret JF; Chauchereau A; Misrahi M; Lescop P; Mantel A; Bailly A; Milgrom E
Hum Reprod; 1994 Jun; 9 Suppl 1():7-11. PubMed ID: 7962473
[TBL] [Abstract][Full Text] [Related]
51. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent.
Souque A; Fagart J; Couette B; Davioud E; Sobrio F; Marquet A; Rafestin-Oblin ME
Endocrinology; 1995 Dec; 136(12):5651-8. PubMed ID: 7588320
[TBL] [Abstract][Full Text] [Related]
52. Modulation of androgen and progesterone receptors by phytochemicals in breast cancer cell lines.
Rosenberg RS; Grass L; Jenkins DJ; Kendall CW; Diamandis EP
Biochem Biophys Res Commun; 1998 Jul; 248(3):935-9. PubMed ID: 9704030
[TBL] [Abstract][Full Text] [Related]
53. The mechanism of action of steroid antagonists: insights from crystallographic studies.
Duax WL; Griffin JF; Weeks CM; Wawrzak Z
J Steroid Biochem; 1988 Oct; 31(4B):481-92. PubMed ID: 3059053
[TBL] [Abstract][Full Text] [Related]
54. Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: structure-activity relationships.
Connor K; Ramamoorthy K; Moore M; Mustain M; Chen I; Safe S; Zacharewski T; Gillesby B; Joyeux A; Balaguer P
Toxicol Appl Pharmacol; 1997 Jul; 145(1):111-23. PubMed ID: 9221830
[TBL] [Abstract][Full Text] [Related]
55. The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values.
Zhang S; Jonklaas J; Danielsen M
Steroids; 2007 Jun; 72(6-7):600-8. PubMed ID: 17509631
[TBL] [Abstract][Full Text] [Related]
56. Effects of antiprogestins on the uterus.
Ouzounian S; Bouchard P; Chabbert-Buffet N
Womens Health (Lond); 2008 May; 4(3):269-80. PubMed ID: 19072476
[TBL] [Abstract][Full Text] [Related]
57. Syntheses and antigestagenic activity of mifepristone derivatives.
Hödl C; Raunegger K; Strommer R; Ecker GF; Kunert O; Sturm S; Seger C; Haslinger E; Steiner R; Strauss WS; Schramm HW
J Med Chem; 2009 Mar; 52(5):1268-74. PubMed ID: 19216549
[TBL] [Abstract][Full Text] [Related]
58. Fluorinated androgens and progestins: molecular probes for androgen and progesterone receptors with potential use in positron emission tomography.
Brandes SJ; Katzenellenbogen JA
Mol Pharmacol; 1987 Sep; 32(3):391-403. PubMed ID: 3499564
[TBL] [Abstract][Full Text] [Related]
59. [Effects of the antagonist of the classical progesterone receptor on ovulation and maturation of common frog (Rana temporaria L.) oocytes in vitro].
Skoblina MN
Ontogenez; 2002; 33(6):465-70. PubMed ID: 12500556
[TBL] [Abstract][Full Text] [Related]
60. Investigations on sterols. 39. Synthesis and progestational activities of some 16-methylene-17 -acetoxy-9 ,10 -pregna-4,6-diene-3,20-dione derivatives.
Hartog J; Wittelaar JI; Morsink L; de Wachter AM
J Med Chem; 1972 Dec; 15(12):1292-7. PubMed ID: 4635977
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
